ArticlePsychiatry and clinical psychopharmacology2025
Prevalence and Independent Risk Factors of Anxiety and Depression Symptoms in Glioma Patients: A Cross-Sectional Analysis.
Article in Psychiatry and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Impact of Sociodemographic Disparities on Health-Related Quality of Life for Adults with Gliomas.Cancers · 2026Review
- Neural Vulnerabilities in Glioblastoma: Rethinking Therapy Through Neuroactive Drug Repurposing.Brain tumor research and treatment · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the current status of anxiety and depression symptoms in patients with brain glioma and identify the risk factors associated with anxiety and depression symptoms. Methods: A total of 105 patients diagnosed with glioma at Longgang Central Hospital of Shenzhen from January 2021 to April 2024 were included in this study. The Hospital Anxiety and Depression Scale (HADS) was used to assess the anxiety and depression symptoms of the patients, who were then grouped based on their scores. Chi-square tests and binary logistic regression analyses were performed to identify the independent risk factors for anxiety and depression symptoms in glioma patients. Results: The average HADS-Anxiety score among glioma patients was 8.72 ± 3.41, with an anxiety symptoms prevalence of 61.90% (65/105). The average HADS-Depression score was 7.73 ± 2.91, with a depression symptoms prevalence of 55.24% (58/105). Among them, 58 patients (55.24%) had both anxiety and depression symptoms, seven patients (6.67%) had only anxiety symptoms, and 40 patients (38.10%) had neither anxiety nor depression. The results of binary tic regression analysis showed that family monthly income, seizures, sleep quality, and cognitive function impairment were independent risk factors for anxiety and depression symptoms ( Conclusion: Glioma patients exhibit a high incidence of anxiety and depression symptoms. The occurrence of these conditions is significantly associated with lower monthly household income, seizure occurrence, sleep disturbances, and cognitive impairment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.